Physician profile
John C Dunham
NPI 1487624896
$1,504.60
in general payments reported to CMS, 2019-2025
23 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $155 · 2021: $101 · 2022: $197 · 2023: $278 · 2024: $255 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $798.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $267.06 | 2019-2021 | |
| Abbvie INC. | $201.67 | 2021-2024 | Vraylar |
| Pfizer INC. | $141.28 | 2022-2025 | |
| Amgen INC. | $120.74 | 2021-2024 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals Lp | $120.37 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $101.25 | 2022-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $77.41 | 2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $73.54 | 2020-2025 | Shingrix, Trelegy Ellipta, Bexsero |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.22 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.57 | 2023 | Trulance, Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.08 | 2021-2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $50.14 | 2024-2025 | Gvoke Hypopen, Keveyis |
| Mylan Specialty L.P. | $42.67 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $20.85 | 2019 | |
| Exact Sciences Corporation | $16.29 | 2025 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $15.59 | 2020 | |
| Hologic Sales and Service, LLC | $15.49 | 2024 | Thinprep 2000 Processor, Aptima |
| Allergan, INC. | $15.00 | 2020 | |
| Esperion Therapeutics, INC. | $13.60 | 2020 | |
| Merck Sharp & Dohme LLC | $13.38 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.55 | 2019 | |
| Novartis Pharmaceuticals Corporation | $10.83 | 2019 | |
| Organon LLC | $9.02 | 2024-2025 | Jada System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dunham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.